Olympus Corp Ord (OCPNF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. I am Takeuchi, Representative Executive Officer. I'd like to thank you all for participating in this conference. There were numerous challenges in FY 2025, including supply chain disruptions due to the Noto Peninsula earthquake, a difficult business environment in China, and unexpected departure of our former CEOs. Despite these headwinds, our business performance remained solid, driven by strong sales of Avis X1 GI endoscopy system in North America throughout the year. Revenue achieved close to the forecast announced in February. Adjusted operating profit was 188.5 billion yen, and adjusted operating margin was 18.9%, both exceeding the forecasts. Our quality and regulatory transformation project, Elevate, is continuing to progress well to meet our commitments to the U.S. FDA. We expect to complete all commitments to the FDA by the end of fiscal year 2026. Our three strategic guiding principles of patient safety and sustainability, innovation for growth, and productivity presented in our company strategy are progressing steadily. We made great progress with Elevate, building a solid foundation and further strengthening our corporate culture to achieve quality management that truly prioritizes patient safety. For FY2026, revenue is expected to grow steadily by 4% after FX adjustment. Adjusted OP is expected to be 175 billion yen with an adjusted operating margin of 17.5%. This is due to strategic investments to strengthen our organizational structure for future sustainable growth and improved profitability. The impact of U.S. tariff policy is not included in our forecast due to the fluidity of the situation. we will continue to take measures to mitigate the impact while prioritizing the continuous provision of our products and services to the medical...